An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
This study looks at a treatment called bb2121 for people with multiple myeloma, a type of blood cancer. The study is for those whose cancer has returned (relapsed) or not responded to treatment (refractory). There are different groups (cohorts) based on past treatments. bb2121 is a special therapy made from a patient’s own cells. It aims to help the immune system attack cancer cells.
- **Duration:** The study involves multiple visits over several months.
- **Eligibility:** Participants must have tried other myeloma treatments before or have early relapse after initial therapy.
- **Risks/Benefits:** Possible benefits are better control of cancer, but there are risks like side effects from bb2121.
Study details
NCT03601078
Celgene
11 July 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.